Memorial Hospital Research Laboratories
The Liang Deng Lab
Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma.
Yang, N., #, Wang, Y.,#, Liu, S., Tariq, S.B., Luna, J. M., MazoG., Tan, A., Zhang, T., Wang, J., Yan, W., Choi, J., Rossi, A., Xiang, J.Z., Rice, C. M., Merghoub,T., Wolchok, J. D., and Deng, L. (2023) OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. Journal Experimental Medicine 220(8):e20221166. Epub 2023 May 5. PMID: 37145142.
Gu, L., Lin, E., Liu, S., Yang, N., Kurtansky, N., Neumann, N., Stoll, J., Lezcano, C., Pulitzer, M., Noor, S., Markova, A., Rossi, A., Dickson, M., and Deng L. (2023) Efficacy of Immunotherapy with Combination of Cryotherapy and Topical Imiquimod for Treatment of Kaposi Sarcoma. Journal of Medical Virology, 95(1):e28396. PMID: 36504005.
Yang, N., Garcia, A., Meyer, Tuschl T., Merghoub, T., Wolchok, J.D., and L. Deng (2022) Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. npj Vaccines (2022) 7(1):120. PMID: 36261460. https://doi.org/10.1038/s41541-022-00542-5.
Yang, N., Luna J.M., Dai, P., Wang, Y., Rice, C.M., and L. Deng. (2022). Lung type II alveolar epithelial cells collaborate with CCR2+ inflammatory monocytes in host defense against poxvirus infection. Nature Communications 13(1):1671. PMID: 35351885. PMCID: PMC896475.
Budhu S, Giese R, Gupta A, … Mazo G, Deng L, Barker CA, Wolchok JD, and Merghoub T (2021). Targeting phosphatidylserine enhances the anti-tumor responses to tumor-directed radiation therapy in a preclinical model of melanoma. Cell Reports 34: 108620.
Liang Deng, MD, PhD
- Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.
- [email protected]
- Email Address
- Office Phone
- View physician profile
- Physician profile
- Office Phone
- Office Fax
- Lab Phone
Get in Touch
Lab Head Email
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Liang Deng discloses the following relationships and financial interests:
Intellectual Property Rights
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].